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A new bifunctional enzyme that displays both aldolase and 
kinase activities has been designed and successfully used in the 
synthesis of aldol adducts, employing DHA as initial donor, with 
an increase in the reaction rate of 20-fold over the parents 10 
enzymes, that can be interpreted in terms of substrate 
channelling. 
The main group of aldolases from the biocatalytic point of 
view is, arguably, the one that uses dihydroxyacetone 
phosphate (DHAP) as donor. DHAP-dependent aldolases have 15 
been thoroughly used to synthesize carbohydrates, 
carbohydrate-like structures, or non-carbohydrate 
compounds.1 Their main drawback is their strict specificity 
for the donor substrate. Besides the efforts to overcome the 
DHAP dependence of aldolases,2 an efficient method of 20 
DHAP preparation is still essential and several chemical and 
enzymatic routes of DHAP synthesis have been described in 
the literature.3  
 Our research group has developed a straightforward multi-
enzyme system for one-pot C-C bond formation.4 This route 25 
integrates a recombinant ATP-dependent DHA kinase from 
Citrobacter freundii CECT 46265 for in situ DHAP formation, 
fuculose-1-phosphate aldolase (F-1PA) for the aldolase 
catalysed reaction and the regeneration of ATP by acetate 
kinase (AK). Although this multi-enzyme system is attractive 30 
since it is a one-pot/one-step route to the phosphorylated aldol 
adduct, a considerable number of issues remain. A key point 
is the number of enzymes that take part in the system because, 
although the different enzymes can be relatively easily 
overproduced in recombinant organisms, the purification of 35 
proteins is widely recognized to be technically and 
economically challenging and in general it is the limiting step 
in bioprocess development.6 One way to reduce the number of 
enzymes to purify is to splice two or more enzymatic 
activities in only one protein creating a hybrid or fusion 40 
enzyme.7 The use of fusion proteins in biotransformation may 
have another, even more interesting effects due to the physical 
association into covalently linked complexes of enzymes that 
catalyse sequential reactions. The close proximity of active 
sites of two enzymes in these multi-enzyme complexes can 45 
provide a substantial substrate channelling in addition to the 
random diffusion path.‡ Some of the potential catalytic 
advantages of substrate channelling include the decrease of 
the transit time required for an intermediate to reach the active 
site of the next enzyme and the protection of chemically labile 50 
intermediates.8 In spite of previously exposed, fusion enzymes 
have been scarcely used in biotransformations in contrast with 
their use in other biotechnological fields like protein 
purification or immobilization of enzymes or receptors for 
microarrays or biosensors preparation.  55 
 Herein, we report the engineering of a new bifunctional 
enzyme (named DLF) that displays both aldolase and kinase 
activities in the same polypeptide chain in order to simplify 
and to improve the catalytic behaviour of the multi-enzyme 
system described above (Scheme 1). 60 
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Scheme 1 Application of the engineered fusion enzyme (DLF) to C-C 
bond formation using DHA as starting ketone. 
 A key point at the moment of designing a fusion protein is 
the possible interactions between subunits that can take place. 65 
Since the DHAK from C. freundii is a dimeric enzyme,9 we 
choose as aldolase partner the fructose-1,6-bisphosphate 
(FBP) aldolase from Staphylococcus carnosus because of its 
monomeric structure.10 In this way, the resulting fusion 
protein should have a dimeric structure. Both enzymes were 70 
fused through a five aminoacid linker. This sequence was 
designed with the aid of the LINKER program11 to be short 
enough to keep closer the active sites in order to reinforce the 
substrate channelling and sufficient flexible to allow the 
native folding of each protein (see the Supplementary 75 
Information). 
 The fusion enzyme DLF was expressed soluble and retained 
both activities with a productivity of 135 and 425 U/L of 
culture broth for the kinase and aldolase activities respectively 
(ratio kinase:aldolase activities nearly 1:3). Peptide mass 80 
fingerprinting verified that purified protein had the DLF 
expected features and sedimentation equilibrium analysis 
confirmed that the fusion protein was a homodimer, as the 
native DHAK (see the Supplementary Information). 
 Steady-state kinetic analysis of the kinase and aldolase 85 
activities in DLF enzyme showed that the fusion of both 
enzymes did not modified significantly either the KM or the 
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turnover number (kcat) of DLF aldolase activity (Table 1). On 
the other hand, both constants were slightly modified on DLF 
kinase activity (Table 1).  
Table 1 Summary of the kinetic constants of the bifunctional DLF and of 
the native enzymes. 5 
   DLF 
 DHAKa FBPAb kinase aldolaseb 
KM (M) 1.22x10-6 1.46x10-5 3.80x10-6 1.88x10-5 
kcat (s-1) 24.13 16.76 8.16 20.30 
kcat/KM (s-1/M) 1.98x107 1.16x104 1.19x106 1.08x104 
a Constant determined for DHA; data taken from reference 5 b Constant 
determined in retro-aldol reaction with FBP as substrate. 
 The KM increase and the kcat decrease of about three times, 
results in a loss of catalytic efficiency (kcat/KM) of the kinase 
activity in the fusion enzyme of about one order of magnitude. 10 
This loss in catalytic efficiency could be attributed to the fact 
that in the fusion enzyme some active centres of the kinase 
were inaccessible for the substrate. However, despite this 
decrease, the kcat/KM value for this activity in the fusion 
enzyme in the order of 106 (s-1/M) is high enough to allow its 15 
use in C-C coupling reactions.  
 To study the proximity or substrate channelling effect, two 
sets of reactions were run in parallel (Scheme 2). In the first 
set, the multi-enzyme system formed by a mixture of the 
native DHAK and FBPA was used to catalyse the 20 
condensation between benzyloxyacetaldehyde (1) and DHAP. 
In the second set of reactions the new bifunctional enzyme 
was employed to catalyse the same reaction. In this study the 
use of the ATP regeneration system was avoided. Since in the 
DLF enzyme the kinase:aldolase activities ratio is fixed at 1:3, 25 
this same ratio was kept in the assay with the mixture of the 
native enzymes (see the Supplementary Information). 
 
Scheme 2 Schematic representation of the free diffusion of the 
intermediate DHAP (▲) in the multi-enzyme system (A) against the 30 
possible substrate channeling in the bifunctional fusion enzyme DLF (B). 
 As it can be observed in Fig. 1, the overall reaction rate 
was much higher in the reaction catalysed by the fusion 
enzyme than in the reaction catalysed by the native non-fused 
enzymes. The overall rate of the coupled reaction catalysed by 35 
DLF was 0.41 μmol/min whereas with the multi-enzyme 
system the overall rate was only of 0.02 μmol/min. That is, 
the physical association of the enzymes produces an increase 
in the aldol reaction rate of 20-folds.  
 40 
Fig.1 Aldol product formation catalysed by 2.66 U aldolase and 0.91 U 
kinase using (○) DLF (0.49 mg of protein) or a mixture (●) of DHAK 
(0.114 mg of protein) and FBPA (0.06 mg of protein).The slope of the 
straight lines corresponds to the overall rate of aldol product formation. 
 This observation is consistent with previously reported 45 
examples in other fusion enzyme systems,12 and it cannot be 
attributed to the different amount of fused enzyme used in 
terms of mg of protein since this difference was lower than 3 
times (see the Supplementary Information). Thus, the results 
obtained can be interpreted in terms of proximity of the active 50 
centres occurred in the fusion enzyme. In an enzymatic 
reaction sequence the transit time is the time required for a 
metabolite to reach the next enzyme in the pathway. Transit 
time must be related with the time of diffusion from one 
active site to the other and is expected to be in the order of 55 
r2E/Ds, where rE is the average separation distance of enzyme 
molecules and Ds is the diffusion coefficient of the 
substrate.13 Thus, DHAP produced by the kinase should have 
a lower transit time to the FBPA active sites in the fusion 
proteins compared with that of the non-fused enzyme system 60 
since rE has been significantly reduces. Another possible 
explanation for the obtained results can be deduced from an 
increased local concentration of the intermediate DHAP. 
Nevertheless, in both cases free diffusion of DHAP to the bulk 
solution is limited because the active centres proximity in the 65 
fused enzyme. 
 A preliminary study of the synthetic applicability of this 
new bifuctional enzyme in the stereoselective C-C bond 
formation was conducted in small scale reactions using DHA 
as starting ketone and benzyloxyacetaldehyde (1), 70 
acetaldehyde (3) and 3-(methylthio)propionaldehyde (5) as 
acceptors (Scheme 1). The percentage of aldol adducts 
obtained after 20 h. of reaction with the different aldehydes 
(Table 2) was of 58.2 for benzyloxyacetaldehyde (1), 82.6 
with acetaldehyde (3) and 67.3 with 75 
(methylthio)propionaldehyde (5). Formation of aldol products 
was established by NMR analysis (see the Supplementary 
Information). In a first approximation to determine if the 
stereoselectivity of the aldol reaction had been modified by  
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  3 
the fusion process, we analysed the stereoisomers formed in 
the DLF catalysed reactions applying the enzymatic assay 
described by Sheldon and co-workers based on the 
reversibility of the aldol reaction.14 In general, the results 
summarized in Table 2 are in agreement with those reported 5 
by Sheldon and co-workers: the aldol reaction catalysed by 
DLF is highly, but far from absolutely, stereospecific for 
products with D-threo configuration and it is strongly 
influenced by the acceptor. In particular, the data regarding 
acetaldehyde (3) are not dissimilar to those reported for the 10 
same aldehyde by Sheldon and co-workers.14 Therefore, we 
can conclude that the fusion process has not influence the 
stereoselectivity of the aldol reaction. 
Table 2 Conversion and ratio of stereoisomeric products formed in DLF 
catalysed reactions.a 15 
Stereoisomer (%)b 
Acceptor Conversion (%) 
D-threo L-threo D-erythro 
1 58.2 79.4 2.1 18.5 
3 82.6 71.8 2.0 26.2 
5 67.3 96.0 0   4.0 
a Only stereoisomers with D-threo, L-threo and D-erythro configuration 
could be detected. b Percentage was calculated with respect to the total 
aldol adduct formed. 
 In conclusion, we have developed a fusion enzyme which 
consists of monomeric fructose-1,6-bisphosphate aldolase 20 
from S. carnosus and the homodimeric dihydroxyacetone 
kinase from C. freundii CECT 4626 with an intervening five 
aminoacids linker. The fusion protein was expressed soluble 
and retained both kinase and aldolase activity with a so good 
catalytic efficiency. The proximity of the active centres in the 25 
fusion enzyme promotes a kinetic advantage as indicate the 
20-fold increment in the overall rate of the aldol reaction. 
Finally, it seems that the fusion has not modified the steric 
course of the aldol reaction catalysed by the bifuctional DLF 
enzyme. 30 
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Materials and General Procedures 
 
Staphylococcus carnosus CECT 4491 was provided from the Spanish Type Culture Collection 
(CECT). E. coli BL21(DE3) competent cells were purchased from Stratagene Co. (San Diego, CA). 
Restriction enzymes, Taq polymerase and T4-DNA ligase were purchased from MBI Fermentas AB 
(Lithuania). Triosephosphate isomerase (TIM), α-glycerophosphate dehydrogenase (αGDH), 
lysostaphin and acetate kinase (AK), were purchased from Sigma-Aldrich (St. Louis, MO). PCR 
primers were purchased from Isogen Life Science (Spain) and the pET-28b(+) expression vector 
was purchased from Novagen. Isopropyl-β-D-thiogalactopyranoside (IPTG) was purchased from 
Applichem GmBH (Germany). Plasmids and PCR purification kits were from Promega (Madison, 
WI) and DNA purification kit from agarose gels was from Eppendorf (Hamburg, Germany). SDS-
PAGE was performed using 10% and 5% acrylamide in the resolving and stacking gels, 
respectively. Gels were stained with Coomassie brilliant blue R-250 (Applichem GmBH, 
Germany). Electrophoresis was always run under reducing conditions, in the presence of 5% β-
mercaptoethanol. Protein and DNA gels were quantified by densitometry using GeneGenius Gel 
Documentation and Analysis System (Syngene, U.K.). Nickel-iminodiacetic acid (Ni2+-IDA) 
agarose was supplied by Agarose Bead Technologies (Spain). Size-exclusion chromatography was 
carried out on a HiLoad 26/60 Superdex 75 PG column controlled using the AKTA-FPLC system 
(GE Healthcare Life Science). All other chemicals were purchased from commercial sources as 
reagent grade. 
 
Cloning, overexpression and purification of FBPA from S. carnosus 
 
DNA manipulation was according to standard procedures.1 DNA template for amplification of the 
fda gene was obtained from the S. carnosus strain CECT 4491. The oligonucleotides 5´-
ATATTCATATGAACCAAGAACAACAATTTGAC-3´ and 5´-
TATTACTCGAGTTAAGCTTTGTTTACTGA-3´ were used as leftward and rightward primers 
respectively (the recognition sequence for NdeI and XhoI are underlined). To extract the DNA, S. 
carnosus cells was suspended in lysis buffer containing Tris 10 mM, EDTA 10 mM, lysozyme 200 
U/mL and lysostaphin 25 U/mL.2 PCR amplification was performed in a 10 μl reaction mixture and 
subjected to 25 cycles of amplification. The cycle conditions were set as follows: denaturation at 
94ºC for 1 min, annealing at 55 ºC for 2 min and elongation at 72 ºC for 1 min. The purified PCR 
product was digested with NdeI and XhoI and ligated into the doubled digested vector pET-28b(+) 
to yield the plasmid pET-fda. This plasmid was transformed into E. coli BL21(DE3) competent 
cells. 
A colony containing the plasmid pET-fda was cultured in Luria-Bertani (LB) broth containing 
kanamycin (26 μg/mL) at 37 ºC with shaking. When the culture reached an O.D600nm of 0.5-0.6, 
FBPA expression was induced with IPTG (0.4 mM) and the temperature was dropped to 30 ºC. The 
culture was maintained O/N. After that, the culture was centrifuged at 3,000 x g during 30 min at 4 
ºC and the resulting pellet was treated with lysozyme and DNase for protein extraction.3  
The recombinant protein containing an N-terminal 6xHis tag was purified in a Ni+2-IDA-agarose 
column pre-equilibrated with sodium phosphate buffer (20 mM, pH 7.5). FBPA was eluted with the 
same buffer containing imidazole 1 M. All the fractions containing protein were pooled together 
and further purified by size-exclusion chromatography on a HiLoad 26/60 Superdex 75 PG column 
controlled using the AKTA-FPLC system (GE Healthcare Life Science). The column was 
                                                 
1 J. Sambrook, E. F. Fritsch, T. Maniatis Molecular cloning. A laboratory manual. 1989. Cold Spring Harbor 
Laboratory Press. Cold Spring Harbor, N.Y 
2 M. Ligozzi, R. Fontana, Afr J Biotechnol 2003, 2, 251-253. 
3 A. Bastida, A. Fernández-Mayoralas, R. Gómez, F. Iradier, J. C. Carretero, E. García-Junceda, Chem. Eur. J. 2001, 7, 
2390–2397 
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developed in 50 mM phosphate buffer pH 7.2 containing NaCl (0.15 M) at a constant flow rate of 
1.0 mL/min 
 
Construction, expression and purification of the bifuctional DLF enzyme 
 
The dhak-l-fda fusion gene was constructed by gene splicing by overlap extension (SFigure 1).4 
This method comprises two PCR steps. In the first PCR step, the dhak gene from C. freundii and the 
fda gene from S. carnosus were amplified separately including sites for the restriction enzymes 
NdeI (5’-dhak) and XhoI (3’-fda). Extremes 3’-dhak and 5’-fda included the 15 nucleotides linker 
sequence (l). These amplified genes were used as templates for a second PCR step. 
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3´
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SFigure 1. Schematic representation of DHAK and FBPA genes splicing by overlap extension. 
 
The sequences of the primers used are shown in the STable 1. The first two PCRs amplification 
were performed in 10 μl reaction mixture and subjected to 25 cycles of amplification. The cycle 
conditions were set as follows: denaturation at 94ºC for 1 min, annealing at 55 ºC for 1 min and 
elongation at 72 ºC for 2 min. A 1:1 mixture of the purified PCR products was used as template in 
the second PCR step. The reaction conditions were identical to the previously described, except for 
the elongation time that was 3 min. After purification, the dhak-l-fda fragment was digested with 
NdeI and XhoI and ligated into the doubled digested vector pET-28b(+) to yield the plasmid pET-
dhak-l-fda. This plasmid was transformed into E. coli BL21(DE3) competent cells. 
Procedure for expression and purification of the bifuctional enzyme were identical to those 
described for the FBPA enzyme except in the IMAC purification step. In this case, previously to 
elute the enzyme with imidazole 1 M, the column was washed with 10 volumes of sodium 
phosphate buffer (20 mM, pH 7.5) containing imidazole 50 mM. 
                                                 
4 R. M.Horton, H. D. Hunt, S. N. Ho, J. K. Pullen, L. R. Pease, Gene, 1989, 77, 61-68. 
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STable 1. Sequences of the primers used to splice the dhak and fda genes. The endonuclease recognition 
sequences are in bold and the linker sequence underlined 
Fragment Primer Sequence Endonuclease 
dhak-l NtNdhak CtFdhak 
5’-ATATTCATATGTCTCAATTCTTTTTT-3’ 
5’-CTGGCCCTGGCCCTGGCCCAGCTCACTCTC-3’ 
NdeI 
- 
l-fda CtScXfda NtFScfda 
5’-TATTACTCGAGTTAAGCTTTGTTTACTGA-3’ 
5’-CAGGGCCAGGGCCAGAACCAAGAACAATTTGACAAA-3’ 
XhoI  
- 
dhak-l-fda NtNdhak CtScXfda 
5’-ATATTCATATGTCTCAATTCTTTTTT-3’ 
5’-TATTACTCGAGTTAAGCTTTGTTTACTGA-3’ 
NdeI 
XhoI 
 
Protein analysis 
 
Amino acid analyses of purified recombinant proteins were performed in the Protein Chemistry 
Service of the Centre of Biological Research (CIB-CSIC) to determine the protein concentration. 
The absorption spectrum of different quantified samples allowed determination of the molar 
extinction coefficient at 280 nm for recombinant FBPA (ε280 = 46292 M-1·cm-1) and for DLF (ε280 = 
77928 M-1·cm-1). 
Peptide mass fingerprint analyses (SFigure 2) from the SDS-PAGE band corresponding to the 
putative FBPA and DLF were performed at the Proteomic Unit of the Spanish National Center of 
Biotechnology (CNB-CSIC). Samples were digested with sequencing grade trypsin overnight at 
37ºC. The analysis by MALDI-TOF mass spectrometry produces peptide mass fingerprints and the 
peptides observed can be collated and represented as a list of monoisotopic molecular weights. Data 
were collected in the m/z range of 800-3600. 20 peptides covering the major part of the amino acid 
sequence of FBPA were identified (SFigure 2A). Almost all the predicted tryptic peptides with 
molecular masses falling in the analyzed m/z range were found in the peptide mass fingerprint of the 
recombinant FBPA. 
A)
MNQEQFDKIKNGKGFIAALDQSGGSTPKALKDYGVEENEYSNDEEMFNLVHDMRTRIITSPAFNGEKILGAILF
EQTMDREVEGKYTGSYLADKGIVPFLKVDKGLAEEADGVQLMKPIPDLDKLLDRANERGIFGTKMRSNILENNK
EAIEKVVKQQFEVAKEIIAAGLVPIIEPEVNINAKDKEAIEANLAEAIKAELDNLKKDQYVMLKLTIPTKVNAY
SELIEHPQVIRVVALSGGYSRDEANKILKQNDGLIASFSRALVSDLNAQQSDAEFNEKLQEAIDTIFDASVNKA 
1447.7069 1175.6061 1521.7459 
2064.0338 
1016.4390 
772.4547
2496.2549
2154.0669
1501.7404 
848.3981 
1513.7774 911.38541766.8985 1564.7552
1007.5222 1206.5857
1977.9019
SQFFFNQRTHLVSDVIDGTIIASPWNNLARLESDPAIRIVVRRDLNKNNVAVISGGGSGHEPAHVGFIGKGMLT
AAVCGDVFASPSVDAVLTAIQAVTGEAGCLLIVKNYTGDRLNFGLAAEKARRLGYNVEMLIVGDDISLPDNKHP
RGIAGTILVHKIAGYFAERGYNLATVLREAQYAANNTFSLGVALSSCHLPQEADAAPRHHPGHAELGMGIHGEP
GASVIDTQNSAQVVNLMVDKLMAALPETGRLAVMINNLGGVSVAEMAIITRELASSPLHPRIDWLIGPASLVTA
LDMKSFSLTAIVLEESIEKALLTEVETSNWPTPVPPREISCVPSSQRSARVEFQPSANAMVAGIVELVTTTLSD
LETHLNALDAKVGDGDTGSTFAAGAREIASLLHRQQLPLDNLATLFALIGERLTVVMGGSSGVLMSIFFTAAGQ
KLEQGASVAESLNTGLAQMKFYGGADEGDRTMIDALQPALTSLLTQPQNLQAAFDAAQAGAERTCLSSKANAGR
ASYLSSESLLGNMDPGAHAVAMVFKALAESELGQGQGQNQEQFDKIKNGKGFIAALDQSGGSTPKALKDYGVEE
NEYSNDEEMFNLVHDMRTRIITSPAFNGEKILGAILFEQTMDREVEGKYTGSYLADKGIVPFLKVDKGLAEEAD
GVQLMKPIPDLDKLLDRANERGIFGTKMRSNILENNKEAIEKVVKQQFEVAKEIIAAGLVPIIEPEVNINAKDK
EAIEANLAEAIKAELDNLKKDQYVMLKLTIPTKVNAYSELIEHPQVIRVVALSGGYSRDEANKILKQNDGLIAS
FSRALVSDLNAQQSDAEFNEKLQEAIDTIFDASVNKA 
1204.5004
2392.1195 
926.4219 
938.4716
1006.50481008.4979 
1058.4949
1106.5243
1086.4090
1189.5472
1381.5256 
1668.7333
1946.8170 
2006.9221
2203.9716
2220.9344 
2595.0438 
1008.5472
1176.6259
1207.6065 
1501.7856
1506.7984
1734.8908
1767.93881978.9352 
2049.0684
2139.1001 
2835.1508 
B)
 
SFigure 2. Peptide mass fingerprint of FBPA from S. carnosus (A) and bifunctional DLF (B). The sequence of the 
identified peptides are shaded and underlined. Molecular mass of each peptide is indicated in Da. Linker sequence in 
the DLF enzyme is marked in yellow.  
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In the case of the DLF peptide mass fingerprinting, 20 peptides covering the DHAK sequence were 
identified and 13 peptides covering the FBPA sequence were also identified (SFigure 2B). Peptide 
mass fingerprinting verified that purified proteins had the expected features of FBPA and DLF 
respectively.  
Sedimentation equilibrium experiments were performed at the Department of Chemical Physics of 
Biological Macromolecules (Institute of Chemical Physics "Rocasolano"; CSIC). The initial 
concentration of the protein used in these experiments was 0.96 mg/mL. These experiments 
confirmed the expected molecular weight and showed that the fusion protein was a homodimer, as 
the native DHAK (SFigure 3). 
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SFigure 3. Sedimentation equilibrium analysis of FBPA (●) and DLF (○). 
 
Enzyme activity assays 
 
Phosphorylation of DHA was measured spectrophotometrically in a coupled enzymatic assay as 
previously described.5 Aldolase activity was spectrophotometrically measured by the retro-aldol 
reaction using fructose-1,6-bisphosphate (FBP) as substrate.6 The aldolase activity assays were run 
at room temperature following the decrease of absorbance at 340 nm ( 340NADHε = 6220 M-1·cm-1) for 5 
minutes in 1 mL reaction mixture containing Tris-HCl buffer (40 mM, pH 8.0), NADH (0.2 μmol), 
α-GDH/TIM (2 U), 1.0 μmol of FBP and the bifunctional DLF or FBPA. 
 
Steady-state kinetic assays 
 
Steady-state kinetic assays with DLF were measured at 25 ºC in 96-well plates in a total volume of 
0.3 mL. Measurements of kinetic parameters for FBP (SFigure 4A) were performed with 5.3 μg/mL 
of purified protein at sixteen different FBP concentrations in the range 0.005-0.25 mM. Assays to 
determine the kinetic parameters for DHA (SFigure 4B) were performed with 24 μg/mL of purified 
DLF at twelve concentrations of substrate under saturating concentrations of [MgATP]2- complex 
(3.75 mM).  
The catalytic constant (kcat) is the result of dividing the Vmax (in units of M x time-1) by the 
concentration (Molar) of enzyme. 
                                                 
5 I. Sánchez-Moreno, L. Iturrate, R. Martín-Hoyos, M. L. Jimeno, M. Mena, A. Bastida, E. García-Junceda, 
ChemBioChem, DOI:10.1002/cbic.200800573. 
6 H. U. Bergmeyer Methods of Enzymatic Analysis vol. 2, 3rd ed.; (1984)  Verlag Chemie: Deerfield, FL. 
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SFigure 4. Substrate kinetics of aldolase (A) and kinase (B) activities for fusion enzyme DLF. The inserts show Hanes-
Woolf plots used for kinetic constants determination. 
 
Steady-state kinetic assays with FBPA were measured as well at 25 ºC in 96-well plates in a total 
volume of 0.3 mL. Measurements of kinetic parameters for FBP (SFigure 5) were performed with 
0.83 μg/mL of purified protein at twenty different FBP concentrations in the range 0.005-0.6 mM.  
Kinetic constants were obtained using the built-in nonlinear regression tools in SigmaPlot 8.0. For 
the determination of apparent kinetic constants (variation of only one substrate), initial velocities 
(Vi) were fitted to the Michaelis-Menten equation 
 
[FBP] (mM)
0.0 0.2 0.4 0.6
V
 (µ
m
ol
·m
in
-1
·m
g-
1 )
0
5
10
15
20
25
30
[FBP] (mM)
0.0 0.2 0.4 0.6
[F
BP
]/V
 (µ
m
ol
·m
g·
U
-1
)
0.005
0.010
0.015
0.020
V
 (µ
m
ol
·m
in
-1
·m
g-
1 )
[F
BP
]/V
 (µ
m
ol
·m
g·
U
-1
)
 
SFigure 5. Substrate kinetic for FBPA from S. carnosus. The insert shows Hanes-Woolf plot used for kinetic constants 
determination. 
 
Proximity Effect study 
 
To study the proximity effect, the rates of the coupled reaction catalysed by DLF or a combination 
of the two native enzymes were measured and compared under same conditions. In both cases, 0.91 
U of kinase activity and 2.66 U of aldolase activity were used. To fit the Units of activity was 
necessary to use a slightly higher amount of DLF in terms of mg of protein. Thus, 0.49 mg of DLF 
was used by a total of 0.175 mg for the sum of DHAK (0.114 mg) and FBPA (0.061). The reactions 
were carried out at room temperature in 1.5 mL of phosphate buffer (20 mM, pH 7.5) containing 
0.05 mmol of DHA, 0.15 mmol of benzyloxyacetaldehyde (1), 12.5 μmol of MgSO4 and 12.5 μmol 
of ATP. At different time, 50 μL aliquots were taken. The reaction was stopped with HClO4 (7%) 
and the aldol product formed quantified by the retro-aldol assay. 
 
Synthetic application of the bifunctional DLF enzyme 
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C-C bond formation reactions catalysed by the fusion enzyme DLF, were carried out at room 
temperature in 1.5 mL of phosphate buffer (20 mM, pH 7.5) containing 0.05 mmol of DHA, 0.15 
mmol of aldehyde acceptor (benzyloxyacetaldehyde (1), acetaldehyde (3) and 3-
(methylthio)propionaldehyde (5) respectively), 0.1 mmol of acetyl phosphate, 12.5 μmol of MgSO4, 
3 U of AK and DLF (1.5-2 U and 3-6 U of kinase and aldolase activities respectively). The 
reactions begin with the addition of 3.4 μmol of ATP. When the consumption of DHA was higher 
than 90 % (~20 h), the reactions were stopped and passed through activated carbon. The eluted was 
freeze-dried for NMR characterization. 
 
Stereochemistry study of aldol reactions catalyzed by DLF enzyme 
 
The determination of the stereoisomeric products formed by bifuctional DLF was carried out 
following the method described by Sheldon and co-workers (SFigure 6).7  
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SFigure 6. Enzymatic determination of stereoisomers of aldol products (2), (4) and (6). Plots show retro-aldol reactions 
catalysed by RAMA (black line), Fuc-1PA (red line) and Rham-1PA (green line). 
 
NMR procedures. 
 
1H and 13C NMR spectra, using D2O as solvent, were recorded on a Varian SYSTEM 500 
spectrometer equipped with a 5 mm HCN cold probe with field z-gradient, operating at 500.13 and 
125.76 MHz for 1H and 13C, respectively. The sample temperature was maintained constant at 298 
K. One-dimensional NMR experiments were performed using standard Varian pulse sequences. 
Two-dimensional [1H, 1H] NMR experiments (gCOSY) were carried out with the following 
parameters: a delay time of 1 s, a spectral width of 3000 Hz in both dimensions, 4096 complex 
points in t2 and 4 transients for each of 256 time increments, and linear prediction to 512. The data 
were zero-filled to 4096 × 4096 real points. Two-dimensional [1H-13C] NMR experiments (gHSQC 
and gHMBC) used the same 1H spectral window, a 13C spectral windows of 15 000 Hz, 1 s of 
relaxation delay, 1024 data points, and 256 time increments, with a linear prediction to 512. The 
data were zero-filled to 4096 × 4096 real points. Typical numbers of transients per increment were 
4 and 16, respectively. 
5-(benzyloxy)-3,4-dihydroxy-2-oxopentyl phosphate (2) 
 
OPO32- OH
OHO
1
2
3
4
O5
CH2Ph
Ar
 
 
                                                 
7 R. Schoevaart, F. v. Rantwijk, R. A. Sheldon, Biotechnol. Bioeng. 2000, 70, 349-352 
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1H NMR (500 MHz, D2O, 298 K): δ 7.2-7.1 (m, 5H, Ar), 4.52 (dd, 1H, J= 18.5, 5.8 Hz, H-1A), 4.40 
(dd, 1H, J= 18.5, 5.8 Hz, H-1B); 4.4-4.3 (m, 2H, CH2Ph), 4.29 (s, 1H, H-3), 4.15-4.05 (m, 1H, H-4), 
3.50-3.45 (m, 1H, H-5A), 3.45-3.40 (m, 1H, H-5B).  
 
3,4-dihydroxy-2-oxopentyl phosphate (4) 
 
OPO32- OH
Me
OHO
1
2
3
4
 
 
1H NMR (500 MHz, D2O, 298 K): δ 4.55 (dd, 1H, J= 18.8, 6.1 Hz, H-1A), 4.45 (dd, 1H, J= 18.8, 6.1 
Hz, H-1B); 4.20 (d, 1H, J= 2.6 Hz, H-3); 4.14 (dq, 1H, J= 6.4, 2.4 Hz, H-4), 1.10 (d, 3H, J= 6.3 Hz, 
Me). 
13C NMR (125 MHz, D2O, 298 K): δ 211.6 (C-2), 78.5 (C-3), 67.9 (C-4), 67.7 (C-1), 18.4 (Me). 
 
3,4-dihydroxy-6-(methylthio)-2-oxohexyl phosphate (6) 
 
OPO32- OH
OHO
1
2
3
4 S
Me5
6
 
 
1H NMR (500 MHz, D2O, 298 K): δ 4.55 (dd, 1H, J= 18.8, 6.6 Hz, H-1A), 4.45 (dd, 1H, J= 18.8, 6.6 
Hz, H-1B); 4.28 (d, 1H, J= 2.2 Hz, H-3); 4.05 (ddd, 1H, J= 14.4, 11.5, 9.2 Hz, H-4), 2.5-2.4 (m, 2H, 
H-6), 1.95 (s, 3H, Me), 1.8-1.7 (m, 2H, H-5). 
13C NMR (125 MHz, D2O, 298 K): δ 211.5 (C-2), 77.7 (C-3), 70.4 (C-4), 68.1 (C-1), 29.6 (C-6), 
23.5 (C-5); 14.3 (Me). 
